Lipum makes a share issue for faster progress
Being a European Commission Horizon 2020 beneficiary has a distinct positive impact on our development.
The 2.2 M€ grant enables us to proceed faster towards a new drug against chronic inflammatory diseases. To further increase the momentum we are now raising additional funding by a share issue. Interested investors get a chance to join the exciting progress.
Dr Einar PonténCEO+46 (0)70-578 34 95Lipum aims for better quality of life for the millions suffering from chronic inflammatory diseases, including children. Distressed by pain, disability, and comorbidities many have to leave a normal working life in advance. We intend to increase their quality of life and decrease the considerable health care and societal costs.
Tags: